RESEARCH



A meta-analysis and systematic review of myocardial infarction-induced cardiomyocyte proliferation in adult mouse heart

Ya Liu^{1†}, Lingyan Liu^{1†}, Pengcheng Zhuang¹, Jiamin Zou¹, Xiaokang Chen¹, Hao Wu¹, Bingjun Lu¹ and Wei Eric Wang^{1*}

Abstract

Background The proliferation capacity of adult cardiomyocytes is very limited in the normal adult mammalian heart. Previous studies implied that cardiomyocyte proliferation increases after injury stimulation, but the result is controversial partly due to different methodologies. We aim to evaluate whether myocardial infarction (MI) stimulates cardiomyocyte proliferation in adult mice.

Methods A comprehensive literature search was conducted through PubMed/Medline, Embase, and Web of Science databases from 1 January 2000 to 21 December 2023. The SYRCLE's Risk of Bias tool for animal experiments was used to evaluate the quality of the literature by two independent reviewers. Twenty-six studies with cell cycle indicators (Ki67⁺, PH3⁺, BrdU/EdU⁺, and AurkB⁺) to evaluate cycling cardiomyocytes were collected for a meta-analysis. Another 10 studies with genetic reporter/tracing systems to evaluate cardiomyocyte proliferation were collected for a systematic review.

Results Evaluating cardiomyocyte proliferation by immunostaining of the cell cycle indicators on heart tissue, the meta-analysis showed that differences of Ki67⁺, PH3⁺, and BrdU/EdU⁺ cycling cardiomyocytes between MI and Sham groups were not statistically significant. In the post-MI heart, the percentages of PH3⁺, BrdU/EdU⁺, and AurkB⁺ cardiomyocytes were not significantly different between the infarct border zone and remote zone. The percentage of Ki67⁺ cardiomyocytes in the infarct border zone was statistically higher than that in the remote zone. Most of the studies (6 out of 10) using genetic reporter/tracing mouse systems showed that the difference in cardiomyocyte proliferation between MI and Sham groups was not statistically significant. Among the other 4 studies, at least 3 studies could not demonstrate that MI stimulates bona fide cardiomyocyte proliferation because of methodological shortages.

Conclusions MI injury increases Ki67⁺ cycling adult mouse cardiomyocytes in infarct border zone. Very little overwhelming evidence shows that MI stimulates bona fide proliferation in the adult heart.


Keywords Cardiomyocyte proliferation, Myocardial infarction, Cell cycle, Heart, Lineage tracing

[†]Ya Liu and Lingyan Liu contributed equally to this work.

*Correspondence: Wei Eric Wang weiericwang@163.com Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.



Background

Myocardial infarction (MI) is a life-threatening heart disease characterized by the occlusion in the coronary arteries, leading to a great loss of functional cardiomyocytes. The current therapies such as reperfusion therapy and medications can only partially delay the pathological remodeling process, but they do not replenish cardiomyocyte numbers to replace the lost myocardium [1].

Fetal and neonatal cardiomyocytes have a remarkable ability to proliferate. When MI or apex resection injury was induced in a postnatal day 1 (P1) mice/pigs, the remaining cardiomyocytes can proliferate to repair the injury and fully restore the cardiac function after 8 weeks. It implies that injuries could stimulate cardiomyocyte proliferation and generate certain amounts of new cardiomyocytes. However, this regenerative capacity diminishes within the first week after birth [2]; injuries at P7 could not recover but instead replaced with scar tissue [3]. In both normal and injured hearts, accumulating evidence has revealed that there were still cardiomyocyte proliferation events, but the efficacies were very low. However, it is not clear whether, in adult heart, MI injury can trigger cardiomyocyte proliferation.

Most studies investigating cardiomyocyte proliferation have been performed using methodology of immunostaining of cell cycle indicator Ki67⁺, PH3⁺, AurkB⁺ or BrdU/EdU incorporation [4]. Some studies showed that MI in adult mice induced marginal cardiomyocytes to reenter the cell cycle and proliferate [5]. In other studies, the absence of changes in cell cycle indicators suggested that MI did not sufficiently induce cardiomyocyte proliferation [6]. However, in adult cardiomyocytes, these methods usually confuse bona fide proliferation with bi/multinucleation and polyploidization. In recent years, genetic reporter or lineage-tracing systems, i.e., mosaic analysis with double markers (MADM) mice [7] and rainbow mice [8], have been used for more precise detection of new cardiomyocyte formation. Since the golden-standard methodology is still lacking, the results by genetic reporter or lineage-tracing mouse systems are also controversial. For example, by combining genetic lineage tracing with stable isotope labeling and multiisotope imaging mass spectrometry, it showed that the rate of new myocyte formation increases about 3 folds following MI injury, with pre-existing cardiomyocytes in the border zone being the dominant source of new cardiomyocytes [9]. Inconsistent results were found in MI model of MADM mice, which showed MI did not stimulate new cardiomyocyte formation [10].

By performing this meta-analysis and systematic review, we analyzed the available data from independent research groups to evaluate whether MI can induce cardiomyocyte proliferation in adult mice. The findings are of significance in understanding the features of cardiac regeneration post-injury and exploring underlying mechanisms for repairing the injured heart.

Methods

Literature search strategy

We conducted the procedures for this systematic review and meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines [11]. The PRISMA checklist is presented in Additional file 1. The registration number is 2,024,120,002 in the International Platform of Registered Systematic Review and Metaanalysis Protocols. A comprehensive literature search was conducted through PubMed/Medline, Embase, and Web of Science databases from 1 January 2000 to 21 December 2023. A series of in vivo studies on estimating the cell cycle markers after MI in adult mice were collected. A full list of search terms for all databases was shown in Additional file 2: Table S1-3. We also checked reference lists of related reviews and all eligible studies for additional trials.

Eligibility and exclusion criteria

Studies were included if they met the following criteria: (1) MI models in adult mice were successfully completed; (2) there was information on cell cycle activity of cardiomyocytes in the MI group vs Sham group or infarct border zone vs remote zone in the same post-MI heart; (3) outcome indicators of proliferative cell cycle must include at least one of followings: Ki67, PH3, BrdU/EdU, and AurkB. Studies were excluded if they met any of the following criteria: (1) studies were reviews, comments, or meeting abstracts; (2) studies were conducted with animal models of neonatal mice; (3) there was missing data about predetermined outcome parameters. Two reviewers performed all screening processes independently (L.Y. and Z.P.). Discrepancies were resolved by discussion and consensus.

Data extraction and quality assessment

Information was recorded on the author, published year, country, sample size in control and experimental groups, mouse strains, age, outcome measures, and time points for outcome measures. The predefined outcomes were the proportions of Ki67⁺, PH3⁺, BrdU/EdU⁺, or AurkB⁺ [12, 13]. The mean and standard deviation (SD) of outcome measures were extracted from the eligible articles. For articles with only figure information, the GetData software was used to extract the values from the figures. Two reviewers (L.L. and Z.P.) independently collected data from each report.

Two reviewers (L.Y. and Z.P.) independently appraised the potential risk of bias (ROB) and quality assessment using SYRCLE's Risk of Bias tool [14], based on 10 domains: random sequence generation, baseline characteristics, allocation concealment, random housing, blinding, random outcome assessment, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other sources of bias. Discrepancies were resolved by consensus.

Statistical analysis

Mean difference (MD) was used as a summary statistic, calculated for each comparison with 95% CI. The standard error (SE) in the study was converted to SD. The pooled effect was calculated by a random or common effect model in this meta-analysis accounting for potential heterogeneity. I^2 statistic was used to evaluate the heterogeneity among studies [15]. If $I^2 > 50\%$, a random effects model was applied.

Subgroup analysis was conducted for different time points for outcome measures post-MI (within 14 days or more than 14 days) and different mouse strains (C57BL/6 J and other strains) considering potential causes of heterogeneity. A leave-one-out meta-analysis conducted sensitivity analyses to evaluate the robustness of results for decisions made.

For all analyses, the statistical significance was set as *p*-value < 0.05. All statistical analyses used the R packages meta, robvis, forestplot, and ggplot2 (version 4.3.1).

Results

Characteristics of the selected studies with both methodologies of cell cycle indicators and genetic reporter/tracing mouse systems

The detailed search strategy and selection results are shown in Fig. 1. The comprehensive searches of Pub-Med/Medline, Embase, and Web of Science databases




Fig. 1 Flowchart of study. The comprehensive searches of PubMed/Medline, Embase, and Web of Science databases yielded 8159 records, and manual searches of reference of reviews and eligible studies identified an additional 2 articles. After removing duplicates, 4747 records were screened by title and abstract, and 171 article texts were screened full text. A total of 26 studies with methodologies of cell cycle indicators (Ki67⁺, PH3⁺, AurkB⁺ or BrdU/EdU incorporation) were included in the meta-analysis

yielded 8159 records, and manual searches of reference of reviews and eligible studies identified an additional 2 articles. The publication dates of the included studies ranged from 2013 to 2023. After removing duplicates, 4747 records were screened by title and abstract, and 171 articles were screened by full text. A total of 26 studies with methodologies of cell cycle indicators (Ki67⁺, PH3⁺, AurkB⁺, or BrdU/EdU incorporation) were included in the meta-analysis, and 10 studies with methodology of genetic reporter/tracing systems were collected for a

systematic review. For all the studies, time points for outcome measurements differed substantially among these studies, ranging from 3 to 63 days post-MI.

Studies using cell cycle indicators showed no significant increase in cardiomyocyte cell cycle activation in MI heart versus Sham heart

In the 26 studies, the methodologies used in cell cycle indicators showed that most of the mice strains were C57BL/6J. Among those studies, 15 studies were included to analyze the effects of MI on cardiomyocyte proliferation between the MI group and the Sham group (Table 1) [16–30]. The results of the ROB and quality assessment are shown in Fig. 2. All studies described the baseline characteristics. However, about half of the studies did not describe the process of random sequence generation, allocation concealment, random outcome assessment, and blinding of outcome assessment. Apart from that, most studies did not report whether there were incomplete outcome data, selective reporting or other biases.

Pooled results of the meta-analysis on cell cycle markers between the MI group and the Sham group are shown in Fig. 3. Among the 15 studies, there were 7 records of cell cycle marker Ki67, 6 of PH3, 9 of BrdU/EdU, and 3 of AurkB. The results of meta-analysis did not find statistically significant differences in percentages of Ki67⁺ (MD = -0.04%, 95% confidence interval [CI]:-0.27 to 0.19), PH3⁺ (MD = -0.03%, 95% CI:-0.22 to 0.16), and BrdU/EdU⁺ (MD = 0.41%, 95%CI:-0.58 to 1.40). The percentage of AurkB⁺ (MD = -0.09%, 95% CI:-0.14 to -0.04) cardiomyocyte was lower in the MI group than that in the Sham group.

Subgroup analyses were conducted to evaluate whether the time-points post-MI and mouse strains influenced the result (Additional file 3: Fig. S1-2). Firstly, we conducted a subgroup analysis at different time points post-MI (\leq 14 days vs. >14 days) (Additional file 3: Fig. S1). The results showed statistical differences in pooled MD of Ki67⁺ (p < 0.01) between two subgroups. The proportion of BrdU/EdU⁺ cardiomyocytes in the MI group was statistically higher than that in the Sham group over 14 days post-MI. However, we did not find significant differences in pooled MD of PH3⁺ (p=0.81), BrdU/EdU⁺ (p=0.20), or AurkB⁺ (p=0.47) between the two subgroups. In addition, we conducted a subgroup analysis in different mouse strains (C57BL/6 J vs. other strains). The results showed that there were no significant differences in pooled MD of Ki67⁺ (p=0.30), PH3⁺ (p=0.19), or BrdU/EdU (p=0.67) between the two subgroups (Additional file 3: Fig. S2). The studies reporting AurkB⁺ used the same mouse strains and were unable to perform subgroup analysis.

Studies with the methodology of cell cycle indicators showed an increase of Ki67⁺ cycling cardiomyocytes in infarct border zone versus remote zone in the same post-MI heart

Among the 26 studies' methodologies of cell cycle indicators, 11 studies were included between infarct border zone and remote zone in the same post-MI heart (Table 2) [6, 26, 31-39]. The results of ROB and quality assessment are shown in Fig. 4. All studies described the baseline characteristics. A few studies did not describe the process of random sequence generation, random housing, and blinding. About half of the studies did not

Study	Years	Country	Sham (n)	MI (n)	Strains	Age	Time-points for outcome measures	Outcome measures		
Ahmad F et al. [16]	2014	USA	4	6	Gsk3afl/fl	8w	21d post-MI	PH3		
Avolio E et al. [17]	2015	UK	3	6	SCID Beige	8w	14d post-MI	Ki67; BrdU/EdU		
Cai B et al. [18]	2020	China	4	3	C57BL/6	8w	14d post-MI	PH3; Aurora B		
Gao X et al. [19]	2022	China	3	3	Kun Ming	8w	14d post-MI	Ki67; PH3		
Gong R et al. [20]	2021	China	3	3	C57BL/6	5-6w	28d post-MI	Ki67; PH3; Aurora B		
Hu Z et al. [21]	2022	China	5	5	C57BL/6	8w	14d post-MI	Ki67; BrdU/EdU; Aurora B		
Li Y et al. [22]	2022	China	4	4	ICR	8w	7d post-MI	BrdU/EdU		
Magadum A et al. [23]	2017	Germany	4	4	ТМСМ	8w	14d post-MI	BrdU/EdU		
Roy R et al. [24]	2019	USA	5	5	C57BL/6 J	8w	14d post-MI	PH3; BrdU/EdU		
Ruchaya PJ et al. [25]	2022	UK	5	5	C57BL/6	8w	42d post-MI	BrdU/EdU		
Xie Y et al. [26]	2014	USA	6	7	SCID-beige	8w	7d post-MI	Ki67;PH3		
Yan W et al. [27]	2020	China	6	6	C57BL/6 J	8w	3d post-MI	Ki67; BrdU/EdU		
Yang D et al. [28]	2017	China	4	4	C57BL/6 J	8w	28d post-MI	BrdU/EdU		
Yifa O et al. [29]	2019	Israel	3	5	C57BL/6 J	12w	4d post-MI	Ki67		
Zhang Y et al. [30]	2019	USA	3	3	C57BI/6	Adults	24d post-MI	BrdU/EdU		


Table 1 Characteristics of the identified studies on cardiomyocyte proliferation between the MI and Sham groups

Random sequence generation Baseline characteristics Allocation concealment Random housing

Random outcome assessment Blinding of outcome assessment Incomplete outcome data Selective reporting

Blinding

Other bias






Fig. 2 Assessment of risk of bias in the included studies on cardiomyocyte proliferation between MI group and Sham group. A Summary of the risk of bias for the included studies. **B** Risk of bias for each individual study

explain the process of allocation concealment, random outcome assessment, blinding of outcome assessment, and selective reporting. Apart from that, only one study described other biases, and none of the studies reported whether there were incomplete outcome data, considering missing data may affect the authenticity of results.

Pooled results of the meta-analysis on cell cycle markers between the border zone and remote zone are shown in Fig. 5. Among the 11 studies, 9 records of cell cycle marker Ki67 were found. Results of the meta-analysis revealed that the percentage of Ki67⁺ cardiomyocytes in the infarct border zone was statistically higher than that in the remote zone (MD=0.23%, 95% CI: 0.11 to 0.35). There were 6 records of PH3, 8 of BrdU/EdU, and 3 of AurkB. Results of meta-analysis showed that the proportion of PH3⁺ (MD=0.01%, 95% CI: -0.01 to 0.04), BrdU/EdU⁺ (MD=0.27%, 95% CI: -0.12 to 0.66), and AurkB⁺ (MD=0.03%, 95% CI: -0.03 to 0.08) cardiomyocytes in the infarct border zone was higher than that in the remote zone, though the difference was not statistically significant.

Results of subgroup analysis in different time points (≤ 14 days and >14 days) were shown in (Additional file 3: Fig. S3). The percentage of Ki67⁺ cardiomyocytes in the border zone was statistically higher than that in the remote zone within 14 days post-MI (MD=0.22%, 95%CI: 0.09 to 0.36), while there was no statistically significant difference over 14-days post-MI. However, we did not find significant differences in pooled MD of Ki67⁺ (p=0.85), PH3⁺ (p=0.32), BrdU/EdU⁺ (p=0.11), or AurkB⁺ (p=0.36) between two subgroups.

Studies with the methodology of genetic reporter/tracing mouse systems showed very few overwhelming evidence that MI stimulates bona fide proliferation in the adult heart In addition, we conducted a systematic review of 10 studies with the methodology of genetic reporter/tracing systems (Table 3) [5, 8–10, 12, 40–44]. The mouse systems including MADM, FUCCI, Rainbow, α DKRC, Mki67, and MerCreMer⁺/ZEG⁺ were included in this study. In most studies (6 out of 10), the difference in cardiomyocyte proliferation between MI and Sham groups was not statistically significant.

Interestingly, among the other 4 studies showing MI stimulated cardiomyocyte proliferation, very few showed overwhelming evidence that MI stimulated bona fide proliferation in the adult heart because of methodological shortages. A study using the Ki67-based genetic system ProTracer for continuous recording of cycling cardiomyocytes documented a 3~7 folds increase of proliferative cardiomyocytes in MI hearts compared with Sham hearts [5]. However, the Ki67-based ProTracer could only record cycling cardiomyocytes but not dividing cardiomyocytes. Three studies showed a mild increase (1 ~ 3 folds) of proliferative cardiomyocytes in MI hearts compared with Sham hearts. A study used co-registration of cardiomyocyte fluorescent labeling and [15N] thymidine labeling of DNA replication and showed that 3.2% of infarct zone cardiomyocytes initiate DNA replication and nuclear division. However, most DNA synthesis that occurs in these cardiomyocytes does not complete cell division [9]. Another study showed that overexpression of four cellcycle regulators robustly increased adult cardiomyocyte proliferation in MADM mouse heart; the proliferation was ~1 fold more in infarcted heart than Sham, and the proliferation was significantly more in border zone and infarct zone than in remote zone [44]. However, the data was based on manipulation of cell-cycle regulator overexpression. The study neither describes the comparison between MI versus Sham baseline level nor describes the comparison between different regions of the post-MI heart in mice without intervention.

Sensitivity analysis

After eliminating each study, sensitivity analysis of the cell cycle markers (Ki67⁺, PH3⁺, BrdU/EdU⁺, and AurkB⁺) showed that the effects between the MI group and Sham group were still stable in general (Additional file 3: Fig. S4). Sensitivity analyses of the effects between the border zone and remote zone were stable after excluding each study (Additional file 3: Fig. S5).

Discussion

The present study analyzed 36 studies in a wide range of 8161 records. Firstly. Meta-analysis of 26 studies with cell cycle activity assays showed that MI did not significantly increase cell cycle activity compared with

(See figure on next page.)

Fig. 3 Meta-analysis of proportion of cell cycle markers between MI and Sham group in identified studies. **A** Proportion of Ki67⁺. **B** Proportion of PH3⁺. **C** Proportion of BrdU/EdU⁺. **D** Proportion of AurkB⁺. Study-specific mean differences (MD) are represented by squares (with their 95% confidence intervals [CIs] as lines). The size of the solid square reflects the weight of each eligible study, which represents the influence of each study on the overall effect. The overall effects are plotted as diamonds, and its intersection with an invalid line (X=0) is considered statistically insignificant. Random effects models were used if I^2 > 50% and p < 0.05 in the heterogeneity test. Results showed no significant increase in cardiomyocyte cell cycle activation in the MI heart versus the Sham heart

		МIg	roup	S	ham g	jroup				
Study	Total	Mean	SD	Total	Mean	SD	Mean Difference	MD	95%-CI	Weight
Avolio E et al, 2015	6	0.04	0.06	3	0.03	0.02	÷.	0.02	[-0.03; 0.07]	16.0%
Gao X et al, 2022	3	0.16	0.09	3	0.11	0.09		0.05	[-0.09; 0.19]	15.2%
Gong R et al, 2021	3	0.43	0.09	3	0.97	0.06		-0.54	[-0.66; -0.42]	15.4%
Hu Z et al, 2022	5	0.22	0.23	5	0.69	0.49		-0.48	[-0.95; -0.00]	9.6%
Xie Y et al, 2014	4	0.28	0.09	4	0.10	0.01		0.18	[0.09; 0.27]	15.7%
Yan W et al, 2020	6	0.03	0.01	6	0.01	0.01	-	0.01	[0.00; 0.03]	16.1%
Yifa O et al, 2019	5	0.57	0.37	3	0.19	0.01			[0.06; 0.71]	12.1%
Random effects model				27				-0.04	[-0.27; 0.19]	100.0%
Heterogeneity: $I^2 = 94\%$, τ	2 = 0.08	360, p <	0.01				-0.5 0 0.5			
8 PH3 ⁺ (%)										
(, , ,		Mig	oup	S	ham g	roup				
Study	Total	Mean					Mean Difference	MD	95%-CI	Weight
Ahmad F et al, 2014	6	0.36	0.21	4	0.11	0.04	· · · · ·	0.25	[0.08; 0.42]	15.3%
Cai B et al, 2020	3	0.34		4	0.72				[-0.45; -0.32]	17.3%
Gao X et al, 2022		0.13							[-0.08; 0.11]	16.8%
Gong R et al, 2021		0.51		3	0.72		. _		[-0.29; -0.12]	17.0%
Roy R et al, 2019		0.19		5	0.03				[0.02; 0.30]	16.1%
Xie Y et al, 2014	4			4	0.04		-		[-0.00; 0.08]	17.5%
Random effects model	24			23				-0.03	[-0.22; 0.16]	100.0%
Heterogeneity: $I^2 = 97\%$, τ^2		18. p <	0.01					0.00	[0.112, 0.10]	1001070
• • ·							-0.4 -0.2 0 0.2 0.4			
C BrdU/EdU+(%)										
Chudu.	Total	MI g Mean			ham g		Mean Difference	MD	05% 01	Waight
Study	Iotai	wean	5D	Iotai	wean	20	Mean Difference	MD	95%-CI	weight
	6	0.94	0.38	3	0.13	0.10		0.81	[0.49; 1.13]	11.9%
Avolio E et al, 2015			2.28	5	7.58	1.01		-4.87	[-7.05; -2.68]	7.6%
Avolio E et al, 2015 Hu Z et al, 2022	5	2.72								4.4 704
		2.72 1.53	0.36	4	0.57	0.34		0.96	[0.47; 1.44]	11.7%
Hu Z et al, 2022 Li Y et al, 2022	4			4 4	0.57 0.01					11.7% 12.0%
Hu Z et al, 2022 Li Y et al, 2022 Magadum A et al, 2017	4	1.53 0.11	0.07		0.01	0.01			[0.03; 0.17]	12.0%
Hu Z et al, 2022 Li Y et al, 2022 Magadum A et al, 2017 Roy R et al, 2019	4 4 5	1.53 0.11 1.51	0.07 0.70	4 5	0.01 0.20	0.01 0.30		0.10 1.31	[0.03; 0.17] [0.65; 1.98]	12.0% 11.4%
Hu Z et al, 2022 Li Y et al, 2022 Magadum A et al, 2017 Roy R et al, 2019 Ruchaya PJ et al, 2022	4 4 5 5	1.53 0.11 1.51 1.72	0.07 0.70 0.53	4 5 5	0.01 0.20 0.29	0.01 0.30 0.85		0.10 1.31 1.43	[0.03; 0.17] [0.65; 1.98] [0.55; 2.32]	12.0% 11.4% 11.0%
Hu Z et al, 2022 Li Y et al, 2022 Magadum A et al, 2017 Roy R et al, 2019 Ruchaya PJ et al, 2022 Yan W et al, 2022	4 4 5 5 6	1.53 0.11 1.51 1.72 0.02	0.07 0.70 0.53 0.01	4 5 5 6	0.01 0.20 0.29 0.01	0.01 0.30 0.85 0.00		0.10 1.31 1.43 0.01	[0.03; 0.17] [0.65; 1.98] [0.55; 2.32] [0.01; 0.02]	12.0% 11.4% 11.0% 12.0%
Hu Z et al, 2022 Li Y et al, 2022 Magadum A et al, 2017 Roy R et al, 2019 Ruchaya PJ et al, 2022	4 5 5 6 4	1.53 0.11 1.51 1.72 0.02	0.07 0.70 0.53 0.01 0.11	4 5 5	0.01 0.20 0.29 0.01 0.02	0.01 0.30 0.85 0.00 0.02		0.10 1.31 1.43 0.01	[0.03; 0.17] [0.65; 1.98] [0.55; 2.32]	12.0% 11.4% 11.0%
Hu Z et al, 2022 Li Y et al, 2022 Magadum A et al, 2017 Roy R et al, 2019 Ruchaya PJ et al, 2022 Yan W et al, 2022 Yang D et al, 2017 Zhang Y et al, 2019	4 5 5 6 4 3	1.53 0.11 1.51 1.72 0.02 0.23	0.07 0.70 0.53 0.01 0.11	4 5 5 6 4 3	0.01 0.20 0.29 0.01 0.02	0.01 0.30 0.85 0.00 0.02		0.10 1.31 1.43 0.01 0.22 2.17	[0.03; 0.17] [0.65; 1.98] [0.55; 2.32] [0.01; 0.02] [0.11; 0.32] [0.99; 3.34]	12.0% 11.4% 11.0% 12.0% 12.0% 10.3%
Hu Z et al, 2022 Li Y et al, 2022 Magadum A et al, 2017 Roy R et al, 2019 Ruchaya PJ et al, 2022 Yan W et al, 2022 Yang D et al, 2017 Zhang Y et al, 2019 Random effects model	4 5 5 4 3 42	1.53 0.11 1.51 1.72 0.02 0.23 2.36	0.07 0.70 0.53 0.01 0.11 1.04	4 5 5 6 4	0.01 0.20 0.29 0.01 0.02	0.01 0.30 0.85 0.00 0.02		0.10 1.31 1.43 0.01 0.22 2.17	[0.03; 0.17] [0.65; 1.98] [0.55; 2.32] [0.01; 0.02] [0.11; 0.32]	12.0% 11.4% 11.0% 12.0% 12.0% 10.3%
Hu Z et al, 2022 Li Y et al, 2022 Magadum A et al, 2017 Roy R et al, 2019 Ruchaya PJ et al, 2022 Yan W et al, 2022 Yang D et al, 2017 Zhang Y et al, 2019	4 5 5 4 3 42	1.53 0.11 1.51 1.72 0.02 0.23 2.36	0.07 0.70 0.53 0.01 0.11 1.04	4 5 5 6 4 3	0.01 0.20 0.29 0.01 0.02	0.01 0.30 0.85 0.00 0.02		0.10 1.31 1.43 0.01 0.22 2.17	[0.03; 0.17] [0.65; 1.98] [0.55; 2.32] [0.01; 0.02] [0.11; 0.32] [0.99; 3.34]	12.0% 11.4% 11.0% 12.0% 12.0% 10.3%
Hu Z et al, 2022 Li Y et al, 2022 Magadum A et al, 2017 Roy R et al, 2019 Ruchaya PJ et al, 2022 Yan W et al, 2022 Yang D et al, 2017 Zhang Y et al, 2019 Random effects model Heterogeneity: $J^2 = 93\%$, τ^2	4 5 5 4 3 42	1.53 0.11 1.51 1.72 0.02 0.23 2.36	0.07 0.70 0.53 0.01 0.11 1.04	4 5 5 6 4 3	0.01 0.20 0.29 0.01 0.02	0.01 0.30 0.85 0.00 0.02		0.10 1.31 1.43 0.01 0.22 2.17	[0.03; 0.17] [0.65; 1.98] [0.55; 2.32] [0.01; 0.02] [0.11; 0.32] [0.99; 3.34]	12.0% 11.4% 11.0% 12.0% 12.0% 10.3%
Hu Z et al, 2022 Li Y et al, 2022 Magadum A et al, 2017 Roy R et al, 2019 Ruchaya PJ et al, 2022 Yan W et al, 2022 Yang D et al, 2017 Zhang Y et al, 2019 Random effects model	4 5 5 4 3 42	1.53 0.11 1.51 1.72 0.02 0.23 2.36	0.07 0.70 0.53 0.01 0.11 1.04	4 5 6 4 3 39	0.01 0.20 0.29 0.01 0.02 0.19	0.01 0.30 0.85 0.00 0.02 0.08		0.10 1.31 1.43 0.01 0.22 2.17	[0.03; 0.17] [0.65; 1.98] [0.55; 2.32] [0.01; 0.02] [0.11; 0.32] [0.99; 3.34]	12.0% 11.4% 11.0% 12.0% 12.0% 10.3%
Hu Z et al, 2022 Li Y et al, 2022 Magadum A et al, 2017 Roy R et al, 2019 Ruchaya PJ et al, 2022 Yan W et al, 2022 Yang D et al, 2017 Zhang Y et al, 2019 Random effects model Heterogeneity: $I^2 = 93\%$, τ^2	4 5 6 4 3 42 $^{2} = 2.13$	1.53 0.11 1.51 1.72 0.02 0.23 2.36	0.07 0.70 0.53 0.01 0.11 1.04 0.01	4 5 6 4 3 39	0.01 0.20 0.29 0.01 0.02 0.19	0.01 0.30 0.85 0.00 0.02 0.08	-6 -4 -2 0 2 4 6	0.10 1.31 1.43 0.01 0.22 2.17	[0.03; 0.17] [0.65; 1.98] [0.55; 2.32] [0.01; 0.02] [0.11; 0.32] [0.99; 3.34] [-0.58; 1.40]	12.0% 11.4% 11.0% 12.0% 12.0% 10.3%
Hu Z et al, 2022 Li Y et al, 2022 Magadum A et al, 2017 Roy R et al, 2019 Ruchaya PJ et al, 2022 Yan W et al, 2022 Yang D et al, 2017 Zhang Y et al, 2019 Random effects model Heterogeneity: $l^2 = 93\%$, τ^2 AurkB ⁺ (%)	4 5 5 6 4 3 $42^{2} = 2.13$	1.53 0.11 1.51 1.72 0.02 0.23 2.36 55, <i>p</i> <	0.07 0.70 0.53 0.01 0.11 1.04 0.01	4 5 6 4 3 39 S Total 5	0.01 0.20 0.29 0.01 0.02 0.19	0.01 0.30 0.85 0.00 0.02 0.08	Mean Difference	0.10 1.31 1.43 0.01 0.22 2.17 0.41	[0.03; 0.17] [0.65; 1.98] [0.55; 2.32] [0.01; 0.02] [0.11; 0.32] [0.99; 3.34] [-0.58; 1.40]	12.0% 11.4% 11.0% 12.0% 10.3% 100.0%
Hu Z et al, 2022 Li Y et al, 2022 Magadum A et al, 2017 Roy R et al, 2019 Ruchaya PJ et al, 2022 Yan W et al, 2022 Yang D et al, 2017 Zhang Y et al, 2019 Random effects model Heterogeneity: $I^2 = 93\%$, τ^2 AurkB ⁺ (%) Study	4 4 5 6 4 3 42 $^{2} = 2.13$ Total 4	1.53 0.11 1.51 1.72 0.02 0.23 2.36 55, <i>p</i> <	0.07 0.70 0.53 0.01 0.11 1.04 0.01 roup SD 0.07	4 5 6 4 3 39 S Total 5	0.01 0.20 0.29 0.01 0.02 0.19	0.01 0.30 0.85 0.00 0.02 0.08	Mean Difference	0.10 1.31 1.43 0.01 0.22 2.17 0.41 MD -0.10	[0.03; 0.17] [0.65; 1.98] [0.55; 2.32] [0.01; 0.02] [0.11; 0.32] [0.99; 3.34] [-0.58; 1.40]	12.0% 11.4% 11.0% 12.0% 12.0% 10.3% 100.0%
Hu Z et al, 2022 Li Y et al, 2022 Magadum A et al, 2017 Roy R et al, 2019 Ruchaya PJ et al, 2022 Yang D et al, 2022 Yang D et al, 2017 Zhang Y et al, 2019 Random effects model Heterogeneity: $I^2 = 93\%$, τ^2 D AurkB ⁺ (%) Study Cai B et al, 2020	4 4 5 6 4 3 42 $^{2} = 2.13$ Total 4	1.53 0.11 1.51 1.72 0.02 0.23 2.36 55, <i>p</i> < MI g Mean 0.23 0.41	0.07 0.70 0.53 0.01 0.11 1.04 0.01 roup SD 0.07 0.02	4 5 6 4 3 39 S Total 5 3	0.01 0.20 0.29 0.01 0.02 0.19	0.01 0.30 0.85 0.00 0.02 0.08	Mean Difference	0.10 1.31 1.43 0.01 0.22 2.17 0.41 MD -0.10 -0.12	[0.03; 0.17] [0.65; 1.98] [0.55; 2.32] [0.01; 0.02] [0.11; 0.32] [0.99; 3.34] [-0.58; 1.40] 95%-C [-0.20; -0.01	12.0% 11.4% 11.0% 12.0% 12.0% 10.3% 100.0% I Weight] 26.4%] 33.7%
Hu Z et al, 2022 Li Y et al, 2022 Magadum A et al, 2017 Roy R et al, 2019 Ruchaya PJ et al, 2022 Yan W et al, 2022 Yang D et al, 2017 Zhang Y et al, 2019 Random effects model Heterogeneity: $I^2 = 93\%$, τ^2 D AurkB ⁺ (%) Study Cai B et al, 2020 Gong R et al, 2021 Hu Z et al, 2022	4 4 5 5 6 4 3 2 2 = 2.13 Total 4 3 4	1.53 0.11 1.51 1.72 0.02 0.23 2.36 55, <i>p</i> < MI g Mean 0.23 0.41	0.07 0.70 0.53 0.01 0.11 1.04 0.01 roup SD 0.07 0.02	4 5 6 4 3 39 S Total 5 3 4	0.01 0.20 0.29 0.01 0.02 0.19	0.01 0.30 0.85 0.00 0.02 0.08	Mean Difference	0.10 1.31 1.43 0.01 0.22 2.17 0.41 MD -0.10 -0.12 -0.06	[0.03; 0.17] [0.65; 1.98] [0.55; 2.32] [0.01; 0.02] [0.11; 0.32] [0.99; 3.34] [-0.58; 1.40] 95%-C [-0.20; -0.01 [-0.20; -0.03 [-0.14; 0.02]	12.0% 11.4% 11.0% 12.0% 10.3% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Hu Z et al, 2022 Li Y et al, 2022 Magadum A et al, 2017 Roy R et al, 2019 Ruchaya PJ et al, 2022 Yang D et al, 2022 Yang D et al, 2017 Zhang Y et al, 2019 Random effects model Heterogeneity: $I^2 = 93\%$, τ^2 D AurkB ⁺ (%) Study Cai B et al, 2020 Gong R et al, 2021	$ \begin{array}{r} 4 \\ 4 \\ 5 \\ 5 \\ 6 \\ 4 \\ 3 \\ 2^2 = 2.13 \end{array} $ Total $ \begin{array}{r} 4 \\ 3 \\ 4 \\ 11 \end{array} $	1.53 0.11 1.51 1.72 0.02 0.23 2.36 55, <i>p</i> < MI g Mean 0.23 0.41 0.10	0.07 0.70 0.53 0.01 0.11 1.04 0.01 roup SD 0.07 0.02	4 5 6 4 3 39 S Total 5 3	0.01 0.20 0.29 0.01 0.02 0.19	0.01 0.30 0.85 0.00 0.02 0.08	Mean Difference	0.10 1.31 1.43 0.01 0.22 2.17 0.41 MD -0.10 -0.12 -0.06	[0.03; 0.17] [0.65; 1.98] [0.55; 2.32] [0.01; 0.02] [0.11; 0.32] [0.99; 3.34] [-0.58; 1.40] 95%-C [-0.20; -0.01 [-0.20; -0.03]	12.0% 11.4% 11.0% 12.0% 10.3% 100.0% I Weight] 26.4%] 33.7%] 39.9%

Fig. 3 (See legend on previous page.)

Study	Years	Country	n	Strains	Age	Time-points for outcome measures	Outcome measures
Boogerd CJ et al. [31]	2023	Netherlands	8	C57BL/6 J	9 w	7 days post-MI	BrdU/EdU
D'Uva G et al. [32]	2015	Israel	6	C57BL/6 J	6 W	21 days post-MI	Ki67; Aurora B
Fan Y et al. [33]	2020	China	3–5	C57BL/6 J	8 w	14 days post-MI	Ki67; PH3; BrdU/EdU; Aurora E
Fang W et al. [34]	2019	China	10	C57BL/6 J	Adult	7 days post-MI	Ki67
Hirose K et al. [35]	2019	USA	4	C57BL/6 J	6–13 w	10 days post-MI	Ki67
Ma WY et al. [36]	2020	China	5	C57BL/6 J	6–8 w	14 days post-MI	PH3; Aurora B
Malliaras K et al. [37]	2013	USA	5	MerCreMer/ZEG	6–8 w	35 days post-MI	BrdU/EdU
Wang WE et al. [38]	2017	China	8	C57BL/6 J	16 w	21 days post-MI	BrdU/EdU
Wang X et al. [6]	2022	USA	6	C57BL/6 J	10–14 w	14 days post-MI	Ki67; PH3; BrdU/EdU
Wang X et al. [6]	2022	USA	5	C57BL/6 J	10–14 w	28 days post-MI	Ki67; PH3; BrdU/EdU
Wang X et al. [39]	2023	China	6	C57BL/6 J	10–12 w	10 days post-MI	Ki67; PH3; BrdU/EdU
Wang X et al. [39]	2023	China	6-10	C57BL/6 J	10–12 w	28 days post-MI	Ki67; PH3; BrdU/EdU
Xie Y et al. [26]	2014	USA	7	C57BL/6 J	8 w	7 days post-MI	Ki67

 Table 2
 Characteristics of the identified studies on cardiomyocyte proliferation between infarct border zone and remote zone in post-MI hearts

Sham. But in post-MI heart, cardiomyocyte cell cycle activity was higher in the infarct board zone compared with the remote zone. Secondly, among the 10 studies with genetic reporter/tracing mouse systems, 6 studies showed MI did not significantly increase new cardiomyocyte formation compared with Sham. In contrast, the other 4 studies showed MI increased it by $1 \sim 7$ folds.

It is known that the proliferation efficacy of cardiomyocytes is very low in the adult normal heart. In a previous study, human samples were examined from the border zone and remote zone of 13 patients who had died 4 to 12 days after infarction. Ki67 expression was detected in 4% of cardiomyocyte nuclei in the border zone and 1% of those in the remote zone. The reentry of cardiomyocytes into the cell cycle resulted in mitotic indexes of 0.08% and 0.03% respectively in the border zone and remote zone [45]. Since a lack of normal hearts as controls, the observation did not compare cell cycle activation between normal and MI. It showed significant differences in distribution between border zone and remote zone in post-MI heart, indicating that MI might stimulate cell cycle activation. Interestingly, another study analyzed 15 human post-MI hearts by detecting Ki67 expression, mitotic bodies, and ploidy status, which indicated that in human infarcts, the entrance of cardiomyocytes into the cell cycle is transient and that endomitosis, leading to polyploidy, rather than mitosis, leading to karyokinesis, is the final fate of cycling cells [46]. These observations in human tissues raised important questions: Does MI stimulate the bona fide proliferation of mammalian adult cardiomyocytes? Does cardiomyocyte proliferation distribute differently in the post-MI heart?

There have been discrepancies among previous studies in terms of the intrinsic level of cardiomyocyte cell cycle activity post-injury. Some studies showed that MI robustly stimulates the division of pre-existing cardiomyocytes. Combining two different pulse-chase approaches-genetic fate-mapping with stable isotope labeling and multi-isotope imaging mass spectrometry-it showed a robust increase of proliferation in the scar border region compared to sham-operated mice [9]. EdU incorporation showed that the number of EdU⁺ cardiomyocytes was over 10 folds compared to remote areas [38]. On the other hand, by using the MADM mouse system which allows unambiguous identification of progeny cells, it showed that MI did not increase the rate of cardiomyocyte division compared with Sham [10]. Either by using EdU incorporation or MADM mouse system, another study showed no significant difference in cardiomyocyte proliferation between infarct border zones and remote areas [43].

The conventional approaches to evaluate the proliferation of adult cardiomyocytes usually include the indicators of DNA replication and nuclear division, such as Ki67, PH3, AurkB staining, and BrdU/EdU incorporation [47]. Distinguishing cell cycle marker




Fig. 4 Assessment of risk of bias in the included studies on cardiomyocyte proliferation between infarct border zone and remote zone. A Summary of the risk of bias for the included studies. B Risk of bias for each individual study

staining from non-specific staining or the staining of non-cardiomyocytes (such as fibroblast or inflammatory cells) can be difficult, which may lead to the potential for methodologic bias and measurement errors [44, 48]. Incomplete cell division in adult cardiomyocytes results in the formation of polyploid or multinuclear cells without any increase in cell number [49]; thus, it often mistakenly equates multinucleation

with genuine cell division. Immunostaining of AurkB presents a more specific cell division but can only show a snapshot of very rare proliferating cardiomyocytes at a single time point. The efficacy of BrdU/EdU⁺ labeling is influenced by the parameters of its administration, such as the timing post-administration, number of injections, and dose. We analyzed the proportion of BrdU/EdU⁺ between the MI group and Sham group with different labeling durations. The studies with a labeling duration time < 14 days showed no difference in BrdU/EdU⁺ cardiomyocytes between the MI group vs. the Sham group, while the studies with a labeling time \geq 14 days showed an increased proportion of BrdU/EdU⁺ cardiomyocytes between the MI and Sham groups. The administration injections and concentrations of BrdU/EdU⁺ labeling by different research groups might also influence the results, but it is difficult to get a statistical conclusion due to the limited number of studies in each group.

This meta-analysis and systematic review can enhance the statistical power by pooling multiple small-sample preclinical studies, the data from different labs and mixed methodologies which helps assess the effects of MI on cardiomyocyte cell-cycle reentry and proliferation. In analyzing 26 mouse studies with cell cycle activity assays, our meta-analysis showed that MI did not significantly increase cell cycle activation compared with Sham. In post-MI hearts, Ki67⁺ cardiomyocyte was significantly more in the infarct board zone compared with the remote zone, while other cell cycle activity indicators did not differ between the two regions. In analyzing 10 studies with genetic reporter/ tracing mouse systems, 6 studies showed MI did not significantly increase cardiomyocyte proliferation compared with Sham. Experiments using the FUCCI [12] and AurkB [41] systems have shown that MI could not increase the number of cardiomyocytes.

Interestingly, among the other 4 studies, at least 3 studies could not demonstrate that MI stimulates bona fide cardiomyocyte proliferation because of methodological shortages. For example, the Ki67-based genetic system ProTracer only records cycling cardiomyocytes in adult hearts [5], since many of the Ki67-expressing cardiomyocytes in the adult heart do not necessarily undergo cell division. The finding in the Ki67-based genetic system ProTracer mouse that more accumulated Ki67⁺ cycling cardiomyocytes in border zone compared with the remote zone is consistent with the meta-analysis results of Ki67⁺ cardiomyocyte distribution in the post-MI heart.

MADM lineage tracing could unequivocally label postcell division daughter cardiomyocytes, although it may underestimate the cell division events. In the three studies using the MADM lineage tracing system, two studies showed no difference in the frequency of single-colored cardiomyocytes. For example, when Cre was induced by sequentially daily injection of tamoxifen for 14 days post-MI, it showed MI did not increase the MADM labeled daughter cardiomyocytes compared with Sham in 56-day-old mice [10]. Only one study with the MADM system reported an increase of post-cytokinesis new cardiomyocytes in the MI heart compared with sham, but the data was based on manipulation rather than the baseline level.

There are several limitations of our study. First, although having screened all relevant literature in recent years, the final included studies in our metaanalysis potentially introduce some bias. We excluded those studies that documented a pro-proliferative effect on post-MI mice but lacked experimental control of the Sham group. Second, current labeling approaches for adult cardiomyocyte proliferation have certain methodological limitations as they may mix the true proliferation of cardiomyocytes with incomplete mitosis like polyploidy and endomitosis. Besides, separating the true cardiomyocyte-positive signals from other surrounding entangled cell signals, especially fibroblasts after myocardial injury, is difficult. Third, the different experiment protocols from different investigators may lead to data complexity.

Conclusions

In conclusion, although the "gold standard method" for determining the proliferation of adult cardiomyocytes is still lacking, this meta-analysis and systematic review try to conclude current understandings of cardiomyocyte cell cycling and proliferation in the post-MI heart. We showed that MI injury might stimulate

⁽See figure on next page.)

Fig. 5 Meta-analysis of the proportion of cell cycle markers between infarct border and remote zone in identified studies. **A** Proportion of Ki67⁺. **B** Proportion of PH3⁺. **C** Proportion of BrdU/EdU⁺. **D** Proportion of AurkB⁺. Study-specific mean differences (MD) are represented by squares (with their 95% confidence intervals [Cls] as lines). The size of the solid square reflects the weight of each eligible study, which represents each study's influence on the overall effect. The overall effects are plotted as diamonds, and its intersection with an invalid line (X=0) is considered statistically insignificant. Random effects models were used if l^2 > 50% and p < 0.05 in the heterogeneity test. Results showed an increase of Ki67⁺ cycling cardiomyocytes in the infarct border zone versus the remote zone in the same post-MI heart




Fig. 5 (See legend on previous page.)

Study	Country	Sham (n)	Sham (n) Injury (n)	Age	Mice	Injury	Time-points for outcome measures	Cardiomyocyte proliferation	Sig
Ali SR et al. [10]	USA	m	L2	⊗ ⊗	β-actinCreER; MADM GT/TG	LAD ligation	4 w	MI did not increase the rate of cardiomyocyte division compared with Sham	No
Alvarez R et al. [12]	USA	~	~	⊗	FUCCI	LAD ligation	LAD ligation 7,10, 14,21 d	Border zone cardiomyocytes exhibit signs of cell cycle re-entry but fail to show new CMs formation (%CMs nuclei)	No
Bradley LA et al. [40]	USA	0	00	≷ ⊗	aDKRC (cardiomyocyte-specific aMHCMerDreMer-Ki67p- RoxedCre)::RLTG (Rox-Lox-tdTo- mato-eGFP)	I/R	2 w	Cycling CMs increase almost 2 folds (espe- cially in the border zone) after I/R (eGFP + CMs per ten-micron short-axis section) (Ml vs. Sham)	Yes
Fu W et al. [41]	China	Ъ	Ŀ	8	Tnnt2-Dre; Aurkb-rox-tdTomato	LAD ligation	2 w	MI did not activate CM proliferation in adult (MI vs. Sham)	No
Kretzschmar K et al. [42]	Netherlands	0	m	8-9 w	Mki67(IRES-CreERT2); LSL-tdTomato	LAD ligation	1 ×	Ischemic injury did not stimulate significant generation of new CMs (%tdTomato + CMs of the total cells) (border zone vs. remote area)	No
Lima Correa B et al. [43]	France	Q,	Q	adult	MADM	LAD ligation 7–9 w	7-9 w	No significant difference of CM proliferation between infarct border zone and remote area (% single-colored CMs of the total labeled cells)	No
Liu X et al. [5]	China	10	10	8-10 w	8–10 w Ki67-CrexER; R26-GFP	LAD ligation	8 X	Increased 3–7 folds of GFP+CMs in MI com- pared with Sham hearts and in border regions compared with remote region (GFP+CMs %)	Yes
		5	5		Ccna2-CrexER; R26-GFP		6 w		
Mohamed TMA et al. [44] USA	USA	Ó	Q	8-9 w	Myh6-cre/Esr1; MADM	LAD ligation	2 w	Increased less than 1 fold of single-colored CMs in the MI group compared with Sham (based on the overexpression of four cell-cycle regulators)	Yes
Senyo SE et al. [9]	USA	m	4	adult	MerCreMer + /ZEG +	LAD ligation	≷ ∞	Approximately 3.2% of the CMs adjacent to the infarct zone had undergone division (total 15N + x mononucleated diploid fraction) (Ml vs. Sham)	Yes
Sereti Kl et al. [8]	USA	9	9	≥ ∞	Rainbow: B-actinCreER; R26VT2/ GK; Nkx2.5CreER; R26VT2/GK; aMHCCreER; R26VT2/GK	LAD ligation	3 W	MI did not activate CM proliferation in adult (border zone vs. remote area) (percent of total clones)	No

cardiomyocyte cell cycle reentry in the adult heart, especially in infarct border zone and labeled with Ki67 expression and that very little overwhelming evidence showed that MI stimulates bona fide proliferation in adult heart.

Abbreviations

MI	Myocardial infarction
P1	Postnatal day 1
MADM	Mosaic analysis with double markers
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analysis
SD	Standard deviation
MD	Mean difference
ROB	Risk of bias
SE	Standard error
CI	Confidence interval
CI	Confidence interval

Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s12916-024-03822-0.

Additional file 1. PRISMA checklist.

Additional file 2: Table S1. Search strategy of PubMed/Medline; Table S2. Search strategy of EMBASE; Table S3. Search strategy of Web of Science.

Additional file 3: Fig. S1 Subgroup analysis of the proportion of cell cycle markers between MI group and Sham group in different observation time-point post-MI; Fig. S2 Subgroup analysis of the proportion of cell cycle markers between border zone and remote zone in different observation time-point post-MI; Fig. S3 Subgroup analysis of the proportion of cell cycle markers between MI group and Sham group in different mouse strains; Fig. S4 Sensitivity analysis of the proportion of cell cycle markers between MI and Sham group. Fig. S5 Sensitivity analysis of the proportion of cell cycle markers between border zone and remote zone.

Acknowledgements

The author would like to thank Prof. Zhide Hu for his assistance with statistical issues in this paper.

Authors' contributions

Ya Liu: Original manuscript preparation, Literature search; Lingyan Liu: Data extraction and analysis, Original manuscript preparation; Pengcheng Zhuang: Literature search, Data extraction; Jiamin Zou, Xiaokang Chen, Hao Wu and Bingjun Lu: Data correction and curation; Wei Eric Wang: Supervision, Review & Editing. All authors read and approved the final manuscript.

Funding

This study was supported by grants from the National Key Research & Development Program of China (2021YFA0805002) and National Natural Science Foundation of China (U20A20344).

Data availability

The data are available from the corresponding authors on reasonable requests.

Declarations

Ethics approval and consent to participate Not applicable.

Consent for publication

All co-authors have provided consent for the final accepted version of the manuscript to be considered for publication in BMC Medicine.

Competing interests

The authors declare no competing interests.

Author details

¹Department of Geriatrics, Southwest Hospital, Third Military Medical University (Army Medical University), 30 Gaotanyan Street, Chongqing 400038, China.

Received: 18 July 2024 Accepted: 13 December 2024 Published online: 31 December 2024

References

- Reuter SP, Soonpaa MH, Field D, Simpson E, Rubart-von der Lohe M, Lee HK, Sridhar A, Ware SM, Green N, Li X, et al. Cardiac troponin l-interacting kinase affects cardiomyocyte S-phase activity but not cardiomyocyte proliferation. Circulation. 2023;147(2):142–53.
- Ye L, D'Agostino G, Loo SJ, Wang CX, Su LP, Tan SH, Tee GZ, Pua CJ, Pena EM, Cheng RB, et al. Early regenerative capacity in the porcine heart. Circulation. 2018;138(24):2798–808.
- Mahmoud AI, Porrello ER, Kimura W, Olson EN, Sadek HA. Surgical models for cardiac regeneration in neonatal mice. Nat Protoc. 2014;9(2):305–11.
- Rigaud VOC, Hoy RC, Kurian J, Zarka C, Behanan M, Brosious I, Pennise J, Patel T, Wang T, Johnson J, et al. RNA-binding protein LIN28a regulates new myocyte formation in the heart through long noncoding RNA-H19. Circulation. 2023;147(4):324–37.
- Liu X, Pu W, He L, Li Y, Zhao H, Li Y, Liu K, Huang X, Weng W, Wang QD, et al. Cell proliferation fate mapping reveals regional cardiomyocyte cellcycle activity in subendocardial muscle of left ventricle. Nat Commun. 2021;12(1):5784.
- Wang X, Wan TC, Lauth A, Purdy AL, Kulik KR, Patterson M, Lough JW, Auchampach JA. Conditional depletion of the acetyltransferase Tip60 protects against the damaging effects of myocardial infarction. J Mol Cell Cardiol. 2022;163:9–19.
- 7. Zong H, Espinosa JS, Su HH, Muzumdar MD, Luo L. Mosaic analysis with double markers in mice. Cell. 2005;121(3):479–92.
- Sereti KI, Nguyen NB, Kamran P, Zhao P, Ranjbarvaziri S, Park S, Sabri S, Engel JL, Sung K, Kulkarni RP, et al. Analysis of cardiomyocyte clonal expansion during mouse heart development and injury. Nat Commun. 2018;9(1):754.
- Senyo SE, Steinhauser ML, Pizzimenti CL, Yang VK, Cai L, Wang M, Wu TD, Guerquin-Kern JL, Lechene CP, Lee RT. Mammalian heart renewal by preexisting cardiomyocytes. Nature. 2013;493(7432):433–6.
- Ali SR, Hippenmeyer S, Saadat LV, Luo L, Weissman IL, Ardehali R. Existing cardiomyocytes generate cardiomyocytes at a low rate after birth in mice. Proc Natl Acad Sci U S A. 2014;111(24):8850–5.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical research ed). 2021;372:n71.
- Alvarez R Jr, Wang BJ, Quijada PJ, Avitabile D, Ho T, Shaitrit M, Chavarria M, Firouzi F, Ebeid D, Monsanto MM, et al. Cardiomyocyte cell cycle dynamics and proliferation revealed through cardiac-specific transgenesis of fluorescent ubiquitinated cell cycle indicator (FUCCI). J Mol Cell Cardiol. 2019;127:154–64.
- Auchampach J, Han L, Huang GN, Kühn B, Lough JW, O'Meara CC, Payumo AY, Rosenthal NA, Sucov HM, Yutzey KE, et al. Measuring cardiomyocyte cell-cycle activity and proliferation in the age of heart regeneration. Am J Physiol Heart Circ Physiol. 2022;322(4):H579-h596.
- Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE's risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14:43.
- Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol. 2012;41(3):818–27.
- Ahmad F, Lal H, Zhou J, Vagnozzi RJ, Yu JE, Shang X, Woodgett JR, Gao E, Force T. Cardiomyocyte-specific deletion of Gsk3a mitigates post-myocardial infarction remodeling, contractile dysfunction, and heart failure. J Am Coll Cardiol. 2014;64(7):696–706.
- 17. Avolio E, Meloni M, Spencer HL, Riu F, Katare R, Mangialardi G, Oikawa A, Rodriguez-Arabaolaza I, Dang Z, Mitchell K, et al. Combined intramyocardial delivery of human pericytes and cardiac stem cells additively

improves the healing of mouse infarcted hearts through stimulation of vascular and muscular repair. Circ Res. 2015;116(10):e81-94.

- Cai B, Ma W, Wang X, Sukhareva N, Hua B, Zhang L, Xu J, Li X, Li S, Liu S, et al. Targeting LncDACH1 promotes cardiac repair and regeneration after myocardium infarction. Cell Death Differ. 2020;27(7):2158–75.
- Gao X, Li H, Zhang W, Wang X, Sun H, Cao Y, Zhao Y, Ji H, Yang F, Ma W, et al. Photobiomodulation drives MiR-136-5p expression to promote injury repair after myocardial infarction. Int J Biol Sci. 2022;18(7):2980–93.
- Gong R, Wang X, Li H, Liu S, Jiang Z, Zhao Y, Yu Y, Han Z, Yu Y, Dong C, et al. Loss of m(6)A methyltransferase METTL3 promotes heart regeneration and repair after myocardial injury. Pharmacol Res. 2021;174:105845.
- Hu Z, Chen P, Wang L, Zhu Y, Chen G, Chen Y, Hu Z, Mei L, You W, Cong W, et al. FGF6 promotes cardiac repair after myocardial infarction by inhibiting the Hippo pathway. Cell Prolif. 2022;55(5):e13221.
- Li Y, Yang M, Tan J, Shen C, Deng S, Fu X, Gao S, Li H, Zhang X, Cai W. Targeting ACSL1 promotes cardiomyocyte proliferation and cardiac regeneration. Life Sci. 2022;294:120371.
- Magadum A, Ding Y, He L, Kim T, Vasudevarao MD, Long Q, Yang K, Wickramasinghe N, Renikunta HV, Dubois N, et al. Live cell screening platform identifies PPARδ as a regulator of cardiomyocyte proliferation and cardiac repair. Cell Res. 2017;27(8):1002–19.
- Roy R, Leigh T, Gao E, Zhang X, Tian Y: Activation or inhibition of PPARαmediated fatty acid β-oxidation does not active cardiomyocyte proliferation in normal or infarcted adult mice. 2019:667964.
- Ruchaya PJ, Lewis-McDougall FC, Sornkarn N, Amin S, Grimsdell B, Shaalan A, Gritti G, Soe KT, Clark JE, Ellison-Hughes GM. Transplantation of skeletal muscle-derived Sca-1(+)/PW1(+)/Pax7(-) interstitial cells (PICs) improves cardiac function and attenuates remodeling in mice subjected to myocardial infarction. Cells. 2022;11(24):4050.
- Xie Y, Ibrahim A, Cheng K, Wu Z, Liang W, Malliaras K, Sun B, Liu W, Shen D, Cheol Cho H, et al. Importance of cell-cell contact in the therapeutic benefits of cardiosphere-derived cells. Stem Cells. 2014;32(9):2397–406.
- 27. Yan W, Lin C, Guo Y, Chen Y, Du Y, Lau WB, Xia Y, Zhang F, Su R, Gao E, et al. N-Cadherin overexpression mobilizes the protective effects of mesenchymal stromal cells against ischemic heart injury through a β -catenindependent manner. Circ Res. 2020;126(7):857–74.
- Yang D, Fu W, Li L, Xia X, Liao Q, Yue R, Chen H, Chen X, An S, Zeng C, et al. Therapeutic effect of a novel Wnt pathway inhibitor on cardiac regeneration after myocardial infarction. Clin Sci (Lond). 2017;131(24):2919–32.
- Yifa O, Weisinger K, Bassat E, Li H, Kain D, Barr H, Kozer N, Genzelinakh A, Rajchman D, Eigler T, et al. The small molecule Chicago Sky Blue promotes heart repair following myocardial infarction in mice. JCI Insight. 2019;4(22):e128025.
- Zhang Y, Gago-Lopez N, Li N, Zhang Z, Alver N, Liu Y, Martinson AM, Mehri A, MacLellan WR. Single-cell imaging and transcriptomic analyses of endogenous cardiomyocyte dedifferentiation and cycling. Cell Discov. 2019;5:30.
- Boogerd CJ, Perini I, Kyriakopoulou E, Han SJ, La P, van der Swaan B, Berkhout JB, Versteeg D, Monshouwer-Kloots J, van Rooij E. Cardiomyocyte proliferation is suppressed by ARID1A-mediated YAP inhibition during cardiac maturation. Nat Commun. 2023;14(1):4716.
- D'Uva G, Aharonov A, Lauriola M, Kain D, Yahalom-Ronen Y, Carvalho S, Weisinger K, Bassat E, Rajchman D, Yifa O, et al. ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nat Cell Biol. 2015;17(5):627–38.
- 33. Fan Y, Cheng Y, Li Y, Chen B, Wang Z, Wei T, Zhang H, Guo Y, Wang Q, Wei Y, et al. Phosphoproteomic analysis of neonatal regenerative myocardium revealed important roles of checkpoint kinase 1 via activating mammalian target of rapamycin C1/ribosomal protein S6 kinase b-1 pathway. Circulation. 2020;141(19):1554–69.
- Fang W, He A, Xiang MX, Lin Y, Wang Y, Li J, Yang C, Zhang X, Liu CL, Sukhova GK, et al. Cathepsin K-deficiency impairs mouse cardiac function after myocardial infarction. J Mol Cell Cardiol. 2019;127:44–56.
- Hirose K, Payumo AY, Cutie S, Hoang A, Zhang H, Guyot R, Lunn D, Bigley RB, Yu H, Wang J, et al. Evidence for hormonal control of heart regenerative capacity during endothermy acquisition. Science. 2019;364(6436):184–8.
- Ma WY, Song RJ, Xu BB, Xu Y, Wang XX, Sun HY, Li SN, Liu SZ, Yu MX, Yang F, et al. Melatonin promotes cardiomyocyte proliferation and heart repair in mice with myocardial infarction via miR-143-3p/Yap/Ctnnd1 signaling pathway. Acta Pharmacol Sin. 2021;42(6):921–31.

- Malliaras K, Zhang Y, Seinfeld J, Galang G, Tseliou E, Cheng K, Sun B, Aminzadeh M, Marbán E. Cardiomyocyte proliferation and progenitor cell recruitment underlie therapeutic regeneration after myocardial infarction in the adult mouse heart. EMBO Mol Med. 2013;5(2):191–209.
- Wang WE, Li L, Xia X, Fu W, Liao Q, Lan C, Yang D, Chen H, Yue R, Zeng C, et al. Dedifferentiation, proliferation, and redifferentiation of adult mammalian cardiomyocytes after ischemic injury. Circulation. 2017;136(9):834–48.
- Wang X, Wan TC, Kulik KR, Lauth A, Smith BC, Lough JW, Auchampach JA. Pharmacological inhibition of the acetyltransferase Tip60 mitigates myocardial infarction injury. Dis Model Mech. 2023;16(5):dmm049786.
- Bradley LA, Young A, Li H, Billcheck HO, Wolf MJ. Loss of endogenously cycling adult cardiomyocytes worsens myocardial function. Circ Res. 2021;128(2):155–68.
- Fu W, Liao Q, Li L, Shi Y, Zeng A, Zeng C, Wang WE. An Aurora kinase B-based mouse system to efficiently identify and analyze proliferating cardiomyocytes. Front Cell Dev Biol. 2020;8:570252.
- Kretzschmar K, Post Y, Bannier-Hélaouët M, Mattiotti A, Drost J, Basak O, Li VSW, van den Born M, Gunst QD, Versteeg D, et al. Profiling proliferative cells and their progeny in damaged murine hearts. Proc Natl Acad Sci U S A. 2018;115(52):E12245-e12254.
- 43. Lima Correa B, El Harane N, Desgres M, Perotto M, Alayrac P, Guillas C, Pidial L, Bellamy V, Baron E, Autret G, et al. Extracellular vesicles fail to trigger the generation of new cardiomyocytes in chronically infarcted hearts. Theranostics. 2021;11(20):10114–24.
- Mohamed TMA, Ang YS, Radzinsky E, Zhou P, Huang Y, Elfenbein A, Foley A, Magnitsky S, Srivastava D. Regulation of cell cycle to stimulate adult cardiomyocyte proliferation and cardiac regeneration. Cell. 2018;173(1):104-116.e112.
- Beltrami AP, Urbanek K, Kajstura J, Yan SM, Finato N, Bussani R, Nadal-Ginard B, Silvestri F, Leri A, Beltrami CA, et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med. 2001;344(23):1750–7.
- Meckert PC, Rivello HG, Vigliano C, González P, Favaloro R, Laguens R. Endomitosis and polyploidization of myocardial cells in the periphery of human acute myocardial infarction. Cardiovasc Res. 2005;67(1):116–23.
- Broughton KM, Sussman MA. Adult cardiomyocyte cell cycle detour: off-ramp to quiescent destinations. Trends Endocrinol Metab. 2019;30(8):557–67.
- Hesse M, Raulf A, Pilz GA, Haberlandt C, Klein AM, Jabs R, Zaehres H, Fügemann CJ, Zimmermann K, Trebicka J, et al. Direct visualization of cell division using high-resolution imaging of M-phase of the cell cycle. Nat Commun. 2012;3:1076.
- Naqvi N, Li M, Calvert JW, Tejada T, Lambert JP, Wu J, Kesteven SH, Holman SR, Matsuda T, Lovelock JD, et al. A proliferative burst during preadolescence establishes the final cardiomyocyte number. Cell. 2014;157(4):795–807.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.